论文部分内容阅读
70例肺癌疗前新鲜标本，采用特异识别簇单克隆抗体C219，检测MDR1P-糖蛋白（MDR1P－glycoprotein，MDR1P－gp）表达与疗效、预后关系。结果示：MDR1P－gp（＋）率34％（24／70）；低分化鳞、腺癌与中及高分化型MDR1P－gp（＋）各为52％（13／25）及21％（6／29），差别显著（P＜0．05，x2=4．4802）；表达（＋）～者占96％（23／24），仅4．2％（1／24）（P=1×109）。表达程度与晚期无关；6例原发瘤与复发转移瘤间仅1例MDR1P－gp表达相符；32例接受化疗，MDR1P－gp与治疗符合率94％（30／32）：MDR1P－gp（＋）与治疗符合率75％，（－）则为61％（P＞0.05）。SCLC与治疗符合率100％（9／9），NSCLC为48％（12／23）（P=0．01），提示（MDR1P－gp表达可能能反映SCLC疗效；中数生存期（MSD）MDR1P－gp（＋）及（－）各为6．5月与13月（P=0.001）Kaplan-Meier曲线及Log-Randtest（P＜0．01x2=7．085）均提示MDR1P-gp（-）者有明显生存期优势。现存5例，（＋）组1例22+月，（－）组4例，48+月3例，37+月1例。故MDR1P－gp表达可能有预测预后意义。
In 70 fresh samples of lung cancer before treatment, monoclonal antibody C219 was used to detect the expression of MDR1P-glycoprotein (MDR1P-gp) and its relationship with efficacy and prognosis. The results showed that the rate of MDR1P-gp(+) was 34% (24/70); poorly differentiated squamous cell adenocarcinoma and moderately and well-differentiated MDR1P-gp(+) were 52% (13/25) and 21% (6) respectively. /29), the difference was significant (P <0.05, x2 = 4.4802); expression (+) - 96% (23/24), only 4.2% (1/24) (P = 1 × 109). The degree of expression has nothing to do with the late stage; 6 cases of primary tumor and recurrent metastasis were only 1 case of MDR1P-gp expression; 32 cases received chemotherapy, MDR1P-gp and treatment rate of 94% (30/32): MDR1P-gp (+ The compliance rate with treatment was 75%, (-) was 61% (P>0.05). The coincidence rate between SCLC and treatment was 100% (9/9), and that of NSCLC was 48% (12/23) (P=0.01), suggesting that MDR1P-gp expression may reflect the efficacy of SCLC; median survival (MSD) MDR1P -gp(+) and (-) were 6.5 and 13 months (P=0.001). Both the Kaplan-Meier curve and Log-Randtest (P<0.01x2=7.085) suggested MDR1P-gp(-). The patients had obvious survival advantage, including 5 cases existing, 1 case 22+ months in (+) group, 4 cases in (-) group, 3 cases in 48+ months, and 1 case in 37+ months.Therefore, MDR1P-gp expression may have prognostic significance. .